110 related articles for article (PubMed ID: 36511379)
21. The prognostic value of the previous nephrectomy in pretreated metastatic renal cell carcinoma receiving immunotherapy: a sub-analysis of the Meet-URO 15 study.
Rebuzzi SE; Signori A; Banna GL; Gandini A; Fornarini G; Damassi A; Maruzzo M; De Giorgi U; Basso U; Chiellino S; Galli L; Zucali PA; Fantinel E; Naglieri E; Procopio G; Milella M; Boccardo F; Fratino L; Pipitone S; Ricotta R; Panni S; Mollica V; Sorarù M; Santoni M; Cortellini A; Prati V; Soto Parra HJ; Santini D; Atzori F; Di Napoli M; Caffo O; Messina M; Morelli F; Prati G; Nolè F; Vignani F; Cavo A; Roviello G; Rescigno P; Buti S
J Transl Med; 2022 Sep; 20(1):435. PubMed ID: 36180954
[TBL] [Abstract][Full Text] [Related]
22. Role of Bone Metastases in Patients Receiving Immunotherapy for Pre-Treated Urothelial Carcinoma: The Multicentre, Retrospective Meet-URO-1 Bone Study.
Raggi D; Giannatempo P; Marandino L; Pierantoni F; Maruzzo M; Lipari H; Banna GL; De Giorgi U; Casadei C; Naglieri E; Buti S; Bersanelli M; Stellato M; Santini D; Vignani F; Roviello G; Veccia A; Caffo O; Losanno T; Calabrò F; Mucciarini C; Pignata S; Necchi A; Maio MD;
Clin Genitourin Cancer; 2022 Apr; 20(2):155-164. PubMed ID: 35000876
[TBL] [Abstract][Full Text] [Related]
23. Pretreatment Blood Parameters Predict Efficacy from Immunotherapy Agents in Early Phase Clinical Trials.
Criscitiello C; Marra A; Morganti S; Zagami P; Viale G; Esposito A; Curigliano G
Oncologist; 2020 Nov; 25(11):e1732-e1742. PubMed ID: 32785940
[TBL] [Abstract][Full Text] [Related]
24. Development and validation of a prognostic scoring model for mortality risk stratification in patients with recurrent or metastatic gastric carcinoma.
Ma T; Wu Z; Zhang X; Xu H; Feng Y; Zhang C; Xie M; Yang Y; Zhang Y; Feng C; Sun G
BMC Cancer; 2021 Dec; 21(1):1326. PubMed ID: 34895168
[TBL] [Abstract][Full Text] [Related]
25. Modified Glasgow prognostic score is a pre-surgical prognostic marker of disease mortality in upper urinary tract urothelial carcinoma.
Tsuzuki S; Kimura S; Fukuokaya W; Yanagisawa T; Hata K; Miki J; Kimura T; Abe H; Egawa S
Jpn J Clin Oncol; 2021 Jan; 51(1):138-144. PubMed ID: 32728722
[TBL] [Abstract][Full Text] [Related]
26. Patient-reported outcomes as a prognostic marker of survival in patients with advanced nonsmall cell lung cancer treated with immunotherapy.
Hopkins AM; Wagner J; Kichenadasse G; Modi N; Rowland A; Sorich MJ
Int J Cancer; 2020 Dec; 147(11):3085-3089. PubMed ID: 32492185
[TBL] [Abstract][Full Text] [Related]
27. Prognostic risk stratification derived from individual patient level data for men with advanced penile squamous cell carcinoma receiving first-line systemic therapy.
Pond GR; Di Lorenzo G; Necchi A; Eigl BJ; Kolinsky MP; Chacko RT; Dorff TB; Harshman LC; Milowsky MI; Lee RJ; Galsky MD; Federico P; Bolger G; DeShazo M; Mehta A; Goyal J; Sonpavde G
Urol Oncol; 2014 May; 32(4):501-8. PubMed ID: 24332646
[TBL] [Abstract][Full Text] [Related]
28. Prognosis of patients with hepatocellular carcinoma treated with immunotherapy - development and validation of the CRAFITY score.
Scheiner B; Pomej K; Kirstein MM; Hucke F; Finkelmeier F; Waidmann O; Himmelsbach V; Schulze K; von Felden J; Fründt TW; Stadler M; Heinzl H; Shmanko K; Spahn S; Radu P; Siebenhüner AR; Mertens JC; Rahbari NN; Kütting F; Waldschmidt DT; Ebert MP; Teufel A; De Dosso S; Pinato DJ; Pressiani T; Meischl T; Balcar L; Müller C; Mandorfer M; Reiberger T; Trauner M; Personeni N; Rimassa L; Bitzer M; Trojan J; Weinmann A; Wege H; Dufour JF; Peck-Radosavljevic M; Vogel A; Pinter M
J Hepatol; 2022 Feb; 76(2):353-363. PubMed ID: 34648895
[TBL] [Abstract][Full Text] [Related]
29. Combined systemic immune-inflammatory index (SII) and prognostic nutritional index (PNI) predicts chemotherapy response and prognosis in locally advanced gastric cancer patients receiving neoadjuvant chemotherapy with PD-1 antibody sintilimab and XELOX: a prospective study.
Ding P; Guo H; Sun C; Yang P; Kim NH; Tian Y; Liu Y; Liu P; Li Y; Zhao Q
BMC Gastroenterol; 2022 Mar; 22(1):121. PubMed ID: 35287591
[TBL] [Abstract][Full Text] [Related]
30. Prognostic role of neutrophil-to-lymphocyte ratio and EPSILoN score in advanced non-small-cell lung cancer patients treated with first-line chemo-immunotherapy.
Zattarin E; Manglaviti S; Apollonio G; Beninato T; Mazzeo L; Massa G; Bottiglieri A; Galli E; De Toma A; Occhipinti M; Brambilla M; Ferrara R; Ganzinelli M; Proto C; Garassino MC; de Braud F; Lo Russo G; Prelaj A
Future Oncol; 2022 Jul; 18(23):2593-2604. PubMed ID: 35722877
[TBL] [Abstract][Full Text] [Related]
31. Prognostic model in patients with metastatic urothelial carcinoma receiving immune checkpoint inhibitors after platinum failure.
Park JH; Park I; Kim IH; Hur JY; Hwang I; Kim C; Kim HJ; Maeng CH; Park K; Lee MY; Lee HJ; Jung JY; Keam B; Park SH; Lee JL
Curr Probl Cancer; 2022 Jun; 46(3):100848. PubMed ID: 35344842
[TBL] [Abstract][Full Text] [Related]
32. Proposed global prognostic score for systemic mastocytosis: a retrospective prognostic modelling study.
Muñoz-González JI; Álvarez-Twose I; Jara-Acevedo M; Zanotti R; Perkins C; Jawhar M; Sperr WR; Shoumariyeh K; Schwaab J; Greiner G; Henriques A; Caldas C; Fernández-Giménez C; Sánchez-Muñoz L; Mayado A; Pérez-Pons A; Schmitt-Graeff A; Duyster J; Tanasi I; Olivieri F; Mora-Casterá E; Luna I; Senent L; Bañas MH; Nuñez-García A; Jurado-Chacón M; Martín-Sánchez G; Colado E; Xicoy B; Gener-Ricós G; Gotlib J; Bonadonna P; Reiter A; Valent P; García-Montero AC; Orfao A
Lancet Haematol; 2021 Mar; 8(3):e194-e204. PubMed ID: 33508247
[TBL] [Abstract][Full Text] [Related]
33. Body Composition as an Independent Predictive and Prognostic Biomarker in Advanced Urothelial Carcinoma Patients Treated with Immune Checkpoint Inhibitors.
Martini DJ; Shabto JM; Goyal S; Liu Y; Olsen TA; Evans ST; Magod BL; Ravindranathan D; Brown JT; Yantorni L; Russler GA; Caulfield S; Goldman JM; Nazha B; Joshi SS; Kissick HT; Ogan KE; Harris WB; Kucuk O; Carthon BC; Master VA; Bilen MA
Oncologist; 2021 Dec; 26(12):1017-1025. PubMed ID: 34342095
[TBL] [Abstract][Full Text] [Related]
34. Prognostic models for newly-diagnosed chronic lymphocytic leukaemia in adults: a systematic review and meta-analysis.
Kreuzberger N; Damen JA; Trivella M; Estcourt LJ; Aldin A; Umlauff L; Vazquez-Montes MD; Wolff R; Moons KG; Monsef I; Foroutan F; Kreuzer KA; Skoetz N
Cochrane Database Syst Rev; 2020 Jul; 7(7):CD012022. PubMed ID: 32735048
[TBL] [Abstract][Full Text] [Related]
35. Host immune-inflammatory markers to unravel the heterogeneous outcome and assessment of patients with PD-L1 ≥50% metastatic non-small cell lung cancer and poor performance status receiving first-line immunotherapy.
Banna GL; Tiseo M; Cortinovis DL; Facchinetti F; Aerts JGJV; Baldessari C; Giusti R; Bria E; Grossi F; Berardi R; Morabito A; Catino A; Genova C; Mazzoni F; Gelibter A; Rastelli F; Macerelli M; Chiari R; Gori S; Mansueto G; Citarella F; Cantini L; Rijavec E; Bertolini F; Cappuzzo F; De Toma A; Friedlaender A; Metro G; Pensieri MV; Porzio G; Ficorella C; Pinato DJ; Cortellini A; Addeo A
Thorac Cancer; 2022 Feb; 13(3):483-488. PubMed ID: 34939342
[TBL] [Abstract][Full Text] [Related]
36. The A.L.A.N. score identifies prognostic classes in advanced biliary cancer patients receiving first-line chemotherapy.
Salati M; Caputo F; Cunningham D; Marcheselli L; Spallanzani A; Rimini M; Gelsomino F; Reggiani-Bonetti L; Andrikou K; Rovinelli F; Smyth E; Baratelli C; Kouvelakis K; Kalaitzaki R; Gillbanks A; Michalarea V; Cascinu S; Braconi C
Eur J Cancer; 2019 Aug; 117():84-90. PubMed ID: 31276980
[TBL] [Abstract][Full Text] [Related]
37. Prognostic Value of Lactate Dehydrogenase in Second-Line Immunotherapy for Advanced Esophageal Squamous Cell Carcinoma.
Li Y; Wang K; Zhao E; Li B; Li S; Dong X; Yuan L; Yang H
Pathol Oncol Res; 2022; 28():1610245. PubMed ID: 35721326
[No Abstract] [Full Text] [Related]
38. The prognostic power of inflammatory indices and clinical factors in metastatic castration-resistant prostate cancer patients treated with radium-223 (BIO-Ra study).
Bauckneht M; Rebuzzi SE; Signori A; Frantellizzi V; Murianni V; Lodi Rizzini E; Mascia M; Lavelli V; Donegani MI; Ponzano M; Gaudiano A; Stazza ML; Licari M; Cavallini L; Laghi V; Cindolo L; Maggi M; Sciarra A; Mammucci P; Sambuceti G; Costa RP; Spanu A; Rubini G; Monari F; De Vincentis G; Fornarini G
Eur J Nucl Med Mol Imaging; 2022 Feb; 49(3):1063-1074. PubMed ID: 34486070
[TBL] [Abstract][Full Text] [Related]
39. Efficacy outcomes and prognostic factors from real-world patients with advanced non-small-cell lung cancer treated with first-line chemoimmunotherapy: The Spinnaker retrospective study.
Banna GL; Cantale O; Muthuramalingam S; Cave J; Comins C; Cortellini A; Addeo A; Signori A; McKenzie H; Escriu C; Barone G; Chan S; Hicks A; Bainbridge H; Pinato DJ; Ottensmeier C; Gomes F
Int Immunopharmacol; 2022 Sep; 110():108985. PubMed ID: 35777264
[TBL] [Abstract][Full Text] [Related]
40. The lung immuno-oncology prognostic score (LIPS-3): a prognostic classification of patients receiving first-line pembrolizumab for PD-L1 ≥ 50% advanced non-small-cell lung cancer.
Banna GL; Cortellini A; Cortinovis DL; Tiseo M; Aerts JGJV; Barbieri F; Giusti R; Bria E; Grossi F; Pizzutilo P; Berardi R; Morabito A; Genova C; Mazzoni F; Di Noia V; Signorelli D; Gelibter A; Macerelli M; Rastelli F; Chiari R; Rocco D; Gori S; De Tursi M; Di Marino P; Mansueto G; Zoratto F; Filetti M; Montrone M; Citarella F; Marco R; Cantini L; Nigro O; D'Argento E; Buti S; Minuti G; Landi L; Guaitoli G; Lo Russo G; De Toma A; Donisi C; Friedlaender A; De Giglio A; Metro G; Porzio G; Ficorella C; Addeo A
ESMO Open; 2021 Apr; 6(2):100078. PubMed ID: 33735802
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
